



BrainCool AB (publ) – the BrainCool™ System product receives reimbursement in South Korea

BrainCool has now received official insurance compensation ("reimbursement") notice of USD 1,260 per treatment for the BrainCool™ System product from the South Korean Ministry of Health. The high level of compensation confirms that BrainCool™ System is considered one of the most advanced systems on the market.

BrainCool's CEO Martin Waleij comments;

- The announcement of insurance compensation is a great success for BrainCool and facilitates the launch in Korea. The decision also confirms that we have a leading product, with a high level of compensation. We also expect to increase the level further in the coming years by creating local clinical evidence for our unique functions in, among other things, selective brain cooling and shivering management.

The market for hypothermia in mainly cardiac arrest and neurology has been established globally without the support of insurance compensation. The fact that it has now been established on a broad basis for several products in South Korea is an indication that the market will be experiencing strong growth. During the autumn, several international clinical studies have also presented statistically significant results in the field, further increasing interest in our focus area and may strengthen guidelines globally.

For more information

Martin Waleij – CEO

+46 - 733 93 70 76

E-mail: martin.waleij@braincool.se

About BrainCool AB (publ)

BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Pain Management. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Spotlight Stock Market.